Evidence-based laboratory medicine in oncology drug development: From biomarkers to diagnostics

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 102-109

  Modur, Vijay ^a   Hailman, Eric ^a,c,d   Barrett, J C ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b ASTRAZENECA   (United Kingdom)

^c HTG Molecular Diagnostics Inc   (United States)

^d ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CRIZOTINIB; DENOSUMAB; IMATINIB; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TRASTUZUMAB;

CANCER THERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DECISION MAKING; DIAGNOSTIC TEST; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; LUNG CANCER; MUTATION; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PROSTATE CANCER; SHORT SURVEY; TOXICITY; TRANSLATIONAL RESEARCH; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; EVIDENCE-BASED MEDICINE; HUMANS; MEDICAL LABORATORY SCIENCE; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872011999     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.191072     Document Type: Short Survey

References (28)

1. Gandhi L, Janne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012;18:3737-42.
2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
3. Rockett JC, Burczynski ME, Fornace AJ, Herrmann PC, Krawetz SA, Dix DJ. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol 2004;194:189-99. (Pubitemid 38083372)
4. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011;29:4688-95.
5. Dubois EA, Rissmann R, Cohen AF. Denosumab. Br J Clin Pharmacol 2011;71:804-6.
6. Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, Tankó LB. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006;62:781-92. (Pubitemid 44521426)
7. Marathe DD, Marathe A, Mager DE. Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharm Drug Dispos 2011;32:471-81.
8. Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, et al. Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res 2012;18:2648-57.
9. Peterson MC, Jang G, Kim W, Gurrola E, Kinsey A, Dansey R. Selection of a phase 3 dose regimen for denosumab based on pharmacokinetic (PK), pharmacodynamic (PD), and safety data from multiple subcutaneous (SC) dosing regimens in breast cancer patients (pts) with bone metastases (BM) [Abstract]. J Clin Oncol 2006 ASCO Annu Meet Proc 2006;24(18 Suppl):3086.
10. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46.
11. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22.
12. Eisenhauer EA. Optimal assessment of response in ovarian cancer. Ann Oncol 2011;22(Suppl 8):viii49-51.
13. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9.
14. Herzog TJ, Vermorken JB, Pujade-Lauraine E, Provencher DM, Jagiello-Gruszfeld A, Kong B, et al. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. Gynecol Oncol 2011;122:350-5.
15. Pickl M, Ruge E, Venturi M. Predictive markers in early research and companion diagnostic developments in oncology. N Biotechnol 2012;29:651-5.
16. Cummings J, Ward TH, Dive C. Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov Today 2010;15:816-25.
17. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009;27:4232-5.
18. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.
19. Lung Cancer Mutation Consortium. http://www.golcmc.com/ (Accessed May 2012).
20. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. (Pubitemid 36962641)
21. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-6.
22. U.S. Food and Drug Administration. Draft guidance for industry and Food and Drug Administration staff - in vitro companion diagnostic devices. http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ ucm262292 .htm (Accessed May 2012).
23. Parkinson DR, Johnson BE, Sledge GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res 2012;18:619-24.
24. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
25. Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, et al. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 2011;17:6812-21.
26. Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res 2011;17:6605-7.
27. Ko JM, Velez NF, Tsao H. Pathways to melanoma. Semin Cutan Med Surg 2010;29:210-7.
28. Accredo Health Group. Advanced oncology solutions. http://www.accredo. com/therapy/aos.html (Accessed May 2012).